MTOR and viral infectious disease: reported the results of 25 patients with ABO‐IRT on a de novo mammalian target of rapamycin inhibitor‐based immunosuppression regimen to prevent allograft rejection without increasing the risk of viral infection, and showed that this regimen was feasible without severe surgical or immunological complications and a low rate of viral infection.71